Related Experiment Video
Updated: Jun 28, 2026
07:19
A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms
Published on: October 21, 2010
Combination antifungal therapy: from bench to bedside
1Division of Hematology/Oncology, University of Florida Shands Cancer Center, P.O. Box 103633, Gainesville, FL 32610, USA.
Current Infectious Disease Reports
|October 24, 2008
Summary
Combination antifungal therapy shows promise for treating invasive fungal infections, including invasive aspergillosis, in immunocompromised patients. Further clinical trials are needed to confirm improved efficacy and reduced resistance.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Invasive fungal infections (IFIs) are a significant cause of mortality, particularly in immunocompromised individuals.
- While newer antifungals have improved outcomes, a critical need exists to enhance treatment efficacy for infections like invasive aspergillosis.
- The emergence of antifungal resistance necessitates exploring novel therapeutic strategies.
Purpose of the Study:
- To review the current evidence on combination antifungal therapy for IFIs.
- To evaluate the potential benefits of combination therapy, including improved efficacy, reduced toxicity, and prevention of resistance.
- To identify gaps in knowledge and advocate for future research directions.
Main Methods:
- A comprehensive review of existing data was conducted.
- Evidence from in vitro studies, animal models, and human clinical trials was analyzed.
- The focus was on assessing the role and impact of combination antifungal strategies.
Main Results:
- Combination antifungal therapy presents a promising approach for managing IFIs.
- Preclinical and some clinical data suggest potential benefits in efficacy and resistance mitigation.
- However, robust clinical trial data, especially for invasive aspergillosis, remains limited.
Conclusions:
- Combination antifungal therapy is a viable strategy to improve outcomes in invasive fungal infections.
- Further randomized, prospective clinical trials are essential to establish definitive evidence, particularly for invasive aspergillosis.
- Optimizing combination regimens could lead to better patient management and reduced antifungal resistance.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...